美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Corgi Beauty, Skincare & Aesthetics ETF

27.91

0.0000

成交量：9

成交額：251.88

市值：139.57萬

市盈率：- -

高：27.91

開：27.91

低：27.91

收：27.91

52周最高：29.89

52周最低：24.32

股本：5.00萬

流通股本：5.00萬

量比：0.07

換手率：0.02%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

Hims & Hers Health 回應FTC訴訟：我們立場堅定，將積極捍衞自身權益，堅決駁斥這些毫無根據的指控

Hims & Hers股價暴跌12.2%：路透社稱美國FTC起訴其向Meta和Snap共享用户健康信息

獨家：美國聯邦貿易委員會起訴Hims & Hers，指控其賬單、取消訂閲及隱私操作違規

獨家報導-美國聯邦貿易委員會（FTC）起訴Hims & Hers公司，指控其向Meta和Snap泄露用户健康信息

傑富瑞上調雅詩蘭黛目標價至88美元

艾伯維(ABBV)股票7月28日盤中上漲3.35%：關鍵驅動因素揭曉

TradingKey中文

解讀世界500強排行榜醫藥板塊：強生繼續「霸榜」，禮來排名上升112位，3家中國企業入選

每日经济新闻

Meta和貝萊德將在德克薩斯州EL Paso開發數據中心園區由後者持股80%

环球市场播报

Sarepta任命前艾伯維高管塞韋裏諾為首席執行官後股價上漲

Kenvue 宣佈：FDA 授予泰諾新非處方配方三年市場獨佔權

FDA批准泰諾®與萘普生複方製劑：首款非處方對乙酰氨基酚（650毫克）與萘普生鈉（220毫克）固定劑量組合

美國FDA批准非處方泰諾複方止痛片

美國FDA批准首款對乙酰氨基酚/萘普生非處方組合產品——泰諾聯用萘普生，提供12小時鎮痛效果

艾利科技推出全新創新成果，藉助整合型Align™數字平台提升Invisalign®治療方案規劃與患者參與度

Genmab與艾伯維就Epcoritamab（Duobody®-CD3xCD20）治療復發/難治性瀰漫大B細胞淋巴瘤的3期EPCORE® DLBCL-1試驗作出澄清

Genmab澄清：總生存期（OS）作為美國3期Epcore® DLBCL-1試驗的唯一主要終點，但未能達到

FDA顧問委員會投票支持將Bpc-157肽納入允許藥房配製清單，Hims & Hers Health股價飆升10%

FDA顧問小組投票決定將廣受歡迎的肽BPC-157列入複方製劑清單

美國FDA顧問小組評估肽類限制，業界促放寬

遠程醫療公司Hims & Hers力促FDA放寬部分肽類准入，股價上漲2%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/GLAM/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GLAM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLAM\",,,,,undefined,":{"symbol":"GLAM","market":"US","secType":"STK","nameCN":"Corgi Beauty, Skincare & Aesthetics ETF","latestPrice":27.9134,"timestamp":1789568878859,"preClose":27.9134,"halted":0,"volume":9,"delay":0,"changeRate":0,"floatShares":50000,"shares":50000,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"09-16 14:23:35 EDT","open":27.9134,"high":27.9134,"low":27.9134,"amount":251.88012,"amplitude":0,"askPrice":28.09,"askSize":1400,"bidPrice":28.05,"bidSize":1400,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"exchange":"CBOE","adjPreClose":27.9134,"nav":28.29,"aum":1414500,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":28.01,"preClose":27.9134,"latestTime":"16:10 EDT","volume":6,"amount":167.4804,"timestamp":1789503007245,"change":0.0966,"changeRate":0.003461,"amplitude":0},"volumeRatio":0.0664,"impliedVol":0.4432,"impliedVolPercentile":0.6024},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLAM\",,,,,undefined,":{"symbol":"GLAM","floatShares":50000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.0664,"shares":50000,"dividePrice":0,"high":27.9134,"amplitude":0,"preClose":27.9134,"low":27.9134,"week52Low":24.3178,"pbRate":"--","week52High":29.89,"institutionHeld":0,"latestPrice":27.9134,"eps":0,"divideRate":0,"volume":9,"delay":0,"ttmEps":0,"open":27.9134,"prevYearClose":25.82,"prevWeekClose":28.0254,"prevMonthClose":28.9677,"prevQuarterClose":27.6454,"fiveDayClose":28.0973,"twentyDayClose":27.9474,"sixtyDayClose":26.16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GLAM\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GLAM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GLAM\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GLAM\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1101602756","title":"Hims & Hers Health 回應FTC訴訟：我們立場堅定，將積極捍衞自身權益，堅決駁斥這些毫無根據的指控","url":"https://stock-news.laohu8.com/highlight/detail?id=1101602756","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101602756?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 01:21","pubTimestamp":1785345694,"startTime":"0","endTime":"0","summary":"面对美国联邦贸易委员会（FTC）提起的诉讼，Hims & Hers Health Inc.（HIMS）正式发声。该公司明确表态，坚信自身立场完全站得住脚，并誓言将采取强有力的法律行动，以抵御这些被其定性为“毫无根据”的指控。在官方回应中，Hims & Hers Health强调，他们不会屈服于压力，反而会以更加积极且坚决的姿态，为自己进行辩护。这一声明，既是对当前法律挑战的直接回应，也彰显了其捍卫公司声誉与商业模式的决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","HIMZ","HIYY","THNR","HIMY","HIMS","HEAL","HMYY","GLAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143480394","title":"Hims & Hers股價暴跌12.2%：路透社稱美國FTC起訴其向Meta和Snap共享用户健康信息","url":"https://stock-news.laohu8.com/highlight/detail?id=1143480394","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143480394?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 00:46","pubTimestamp":1785343563,"startTime":"0","endTime":"0","summary":"Hims & Hers Health Inc.股价今日大幅下挫，跌幅高达12.2%。据路透社报道，美国联邦贸易委员会 已对该公司提起诉讼，指控其未经用户同意，擅自将用户的健康数据传送给Meta Platforms, Inc.和Snap Inc.。如果这些指控属实，Hims & Hers将面临严重的法律后果和声誉危机。事件的核心在于，Hims & Hers被指控利用了其平台上用户的健康信息，并将这些数据分享给Meta和Snap这两大社交媒体巨头。目前，Hims & Hers方面尚未就此事件发表正式声明，但市场显然已经用脚投票，给出了最直接的回应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","LU2125154935.USD","LU0308772762.SGD","LU1116320737.USD","LU2417539215.USD","LU0011850046.USD","IE00BK4W5L77.USD","LU0820562030.AUD","HK0000914686.HKD","LU1551013425.SGD","LU1069344957.HKD","LU0006306889.USD","LU2458330169.SGD","LU2404859741.USD","LU0528227936.USD","LU1988902786.USD","LU1914381329.SGD","LU0642271901.SGD","LU2756315318.SGD","LU1823568750.SGD","LU2272731600.USD","LU0127658192.USD","LU0072462426.USD","IE00BJTD4V19.USD","IE000WAW04H5.SGD","LU1564329628.SGD","LU1992135472.HKD","LU0348723411.USD","HK0000304797.USD","LU2347655073.USD","LU0265550359.USD","LU0690374961.EUR","BK4543","LU1084165304.USD","LU0957791311.USD","OGIG","LU1116320901.HKD","LU0203201768.USD","LU2458330243.SGD","LU1232071149.USD","IE00B19Z9505.USD","BK4592","IE00BFSS7M15.SGD","LU1201861249.SGD","LU1815336760.USD","LU1804176565.USD","IE00B19Z8X17.USD","IE00BK4W5M84.HKD","LU0444971666.USD","SGXZ51526630.SGD","LU1868837300.USD","LU2247934214.USD","LU2381873111.SGD","LU1235294995.USD","LU0198837287.USD","LU1868836914.USD","SG9999015952.SGD","LU2087621335.USD","LU1718418525.SGD","LU2764263039.SGD","LU2463028550.USD","LU0784385840.USD","LU2430703178.SGD","IE00B4YYXB79.USD","LU0154236417.USD","LU2168564222.USD","LU0256863811.USD","LU0162691827.USD","LU2896262040.SGD","GLAM","IE00BQXX3D17.EUR","LU1720051017.SGD","LU2430703095.HKD","LU1732799900.SGD","LU2168564149.EUR","SNAP","LU0323591593.USD","LU0788109477.HKD","LU0265550946.USD","LU2505996509.AUD","IE000KEQY171.SGD","BK4077","LU2360032135.SGD","LU0267386448.USD","IE00BWXC8680.SGD","LU0345769128.USD","LU0553294199.USD","LU2213496289.HKD","IE0034235303.USD","SG9999014906.USD","BK4196","LU2473716301.USD","LU0203345920.USD","LU0466842654.USD","LU1868836757.USD","LU0276348264.USD","LU1629891620.HKD","LU0210536198.USD","LU1145028129.USD","IE00B4JS1V06.HKD","SG9999004303.SGD","SG9999017495.SGD","LU2746668974.SGD","LU1564329461.SGD","LU2236285917.USD","SOCL","META","LU0211328371.USD","LU2461242641.AUD","HMYY","LU1280957306.USD","LU0552385451.USD","IE000SO60NU8.SGD","LU0672654240.SGD","GB00B4LPDJ14.GBP","LU2265009873.SGD","LU1670711040.USD","LU2168564495.EUR","SG9999002224.SGD","LU2097829019.USD","LU2317271919.USD","LU1564329115.USD","LU0061474960.USD","IE00BJJMRY28.SGD","LU1267930490.SGD","LU1489326972.SGD","HK0000304805.HKD","LU2404859667.USD","IE000ITXATA3.USD","IE0009356076.USD","LU1074936037.SGD","LU0738911758.USD","IE00BQXX3F31.USD","LU1242518857.USD","LU2264538146.SGD","LU2237957811.SGD","LU0726765562.USD","IE0003U64NQ7.SGD","THNR","LU0912757837.SGD","GB00B4QBRK32.GBP","LU0211327993.USD","LU0353189680.USD","IE000BZT7R73.USD","LU1564329032.USD","LU1778281490.HKD","LU2106854487.HKD","LU0068578508.USD","LU0310799852.SGD","LU0787776722.HKD","LU1992135399.USD","LU1366192091.USD","LU0985320562.USD","LU0170899867.USD","LU2237957902.USD","LU0077335932.USD","LU2552382215.SGD","LU0256863902.USD","SG9999002232.USD","LU0795875169.SGD","LU1496350502.SGD","LU2125154778.USD","LU1791710582.SGD","LU2756315664.SGD","LU1066053197.SGD","IE00B1BXHZ80.USD","METW","FBL","LU1852331112.SGD","LU2456880835.USD","LU2023250504.SGD","LU1551013342.USD","IE00B775H168.HKD","LU0320765059.SGD","LU0444973449.USD","LU1720051108.HKD","LU0433182093.SGD","SG9999014914.USD","LTL","IE00BJLML261.HKD","LU2133065610.SGD","IE000W1ABFV2.USD","LU0823434740.USD","LU2361045086.USD","LU0708995401.HKD","LU0878866978.SGD","VOX","XDAT","GAMR","METU","LU2592432038.USD","IE00B7KXQ091.USD","SG9999014898.SGD","LU0061474705.USD","SG9999015986.USD","LU0203202063.USD","LU0354030438.USD","LU0979878070.USD","BK4585","IE0001KFT4U8.USD","IE00BFSS8Q28.SGD","LU2272731865.HKD","LU0210528500.USD","LU0210533765.USD","IE0004445239.USD","LU2357305700.SGD","LU1674673428.USD","LU0082616367.USD","IE0034235188.USD","LU1670710661.SGD","LU0072461881.USD","LU1316542783.SGD","IE00BQXX3C00.GBP","LU2746668461.USD","SG9999015978.USD","LU0096364046.USD","LU0784384876.USD","LU1261432733.SGD","IE000YTNTUN2.SGD","LU2168564065.EUR","LU2322448957.HKD","HIMY","IE0004445015.USD","LU2543165471.USD","FCOM","LU2168563687.JPY","LU0980610538.SGD","HIMZ","LU1697837992.HKD","IE00BMPRXQ63.HKD","LU1366333091.USD","IE0005OL40V9.USD","LU0354030511.USD","LU0724617625.USD","LU1035775433.USD","LU2360106780.USD","BK4507","LU0149725797.USD","HK0000914660.USD","LU0820561818.USD","XLC","LU0130102774.USD","LU0203347892.USD","LU2023250843.SGD","IE0000B7K699.USD","LU0823434583.USD","LU1435385759.SGD","LU2361044949.HKD","BK4508","SG9999018857.SGD","SG9999015945.SGD","LU1815333072.USD","LU1861558580.USD","SG9999014880.SGD","LU2403377893.USD","LU0080751232.USD","NULC","SGXZ31699556.SGD","LU0949170426.SGD","FBY","BK4554","IE00B19Z3B42.SGD","IE00BJTD4N35.SGD","LU1267930730.SGD","LU1242518931.SGD","SG9999001077.SGD","LU0208291251.USD","IE00B19Z3581.USD","LU2250418816.HKD","LU0106261372.USD","BK4524","LU1861559042.SGD","LU1429558221.USD","LU0314104364.USD","LU1059921491.USD","LU2420271590.USD","LU0943347566.SGD","LU0070217475.USD","BK4551","LU0316494557.USD","SGXZ81514606.USD","LU1917777945.USD","GXPC","LU2023250330.USD","LU0225283273.USD","LU2063271972.USD","LU1670711123.USD","LU0053666078.USD","LU0784383803.USD","LU0719512351.SGD","LU2361044865.SGD","LU0320765489.SGD","IE00BN29S564.USD","LU1003077747.HKD","BK4588","IE00BMPRXN33.USD","LU0823421333.USD","LU0784385170.HKD","IE000F7OJYX1.SGD","LU0234570918.USD","LU1064131342.USD","LU0889565833.HKD","METD","LU0786609619.USD","LU1674673691.USD","LU0096362180.USD","SGXZ23171101.USD","LU0174119429.USD","LU0061475181.USD","FBYY","LU0109392836.USD","LU0683600562.USD","LU0690374615.EUR","GB00BDT5M118.USD","LU0823421416.USD","LU0882574139.USD","LU2764262908.HKD","LU1732800096.USD","LU0079474960.USD","LU2552382132.HKD","HEAL","LU0957808578.USD","BK4587","LU2272731782.SGD","LU1868836591.USD","LU2505996681.GBP","LU2087625088.SGD","LU1642822529.SGD","LU1803068979.SGD","LU0215105999.USD","IE00BJJMRX11.SGD","SG9999018865.SGD","LU0795875086.SGD","LU0133085943.USD","LU2552382058.USD","LU2720916845.USD","LU2860962120.EUR","LU2347655156.SGD","TRUC","LU0476273544.USD","LU0689472784.USD","LU1127390331.HKD","LU1119994496.HKD","HIMS","LU0640476718.USD","LU2430703251.USD","LU0157215616.USD","LU0345769631.USD","LU2764263203.CNY","LU1791710400.SGD","LU2065171311.SGD","LU2602419157.SGD","BK4576","LU0648001328.SGD","LU1301847155.USD","IE00BMPRXR70.SGD","LU0056508442.USD","SNAG","LU1670628061.USD","IE00B3SWFQ91.USD","IE000MB6IJN5.SGD","LU1670627923.USD","LU2054465674.USD","LU1548497426.USD","LU1868837136.USD","LU0949170772.SGD","LU2462157665.USD","IE00B1XK9C88.USD","LU1153585028.USD","RSPC","SGXZ99366536.SGD","HIYY","LU0417517546.SGD","LU0211331839.USD","LU1571399168.USD","LU2326559502.SGD","IE00BKDWB100.SGD","LU1974910355.USD","LU1814569148.SGD","LU1046421795.USD","IE00B7SZLL34.SGD","LU0661504455.SGD","LU0234572021.USD","IE0002270589.USD","LU0070302665.USD","LU1839511570.USD","LU0964807845.USD","LU1699723380.USD","LU2065169927.USD","LU0097036916.USD","LU2322448791.USD","LU0353189763.USD","IE00B19Z8W00.USD","LU2242650005.HKD","LU1670710588.SGD","LU2487616109.SGD","LU0985489474.SGD","METV","LU0820561909.HKD","IE00B5949003.HKD","LU0545039389.USD","LU2065171402.SGD","LU2065170008.USD","LU2462591350.SGD","LU0109391861.USD","IE0009G5SDU7.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184720821","title":"獨家：美國聯邦貿易委員會起訴Hims & Hers，指控其賬單、取消訂閲及隱私操作違規","url":"https://stock-news.laohu8.com/highlight/detail?id=1184720821","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184720821?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 00:31","pubTimestamp":1785342705,"startTime":"0","endTime":"0","summary":"独家消息源透露，美国联邦贸易委员会（FTC）已正式对远程医疗公司Hims & Hers Health Inc.提起法律诉讼，矛头直指其收费流程、订阅取消政策以及用户隐私保护方面的多项不规范操作。一位FTC发言人在官方声明中确认了这一消息，使得这起备受瞩目的监管行动公之于众。据悉，此次诉讼的核心争议点在于，该公司是否在账单结算、取消订阅的便捷性上误导消费者，并可能涉及不当收集或使用用户健康数据。这一法律行动的细节仍在持续发酵中，市场对此反应强烈，投资者正密切关注后续的庭审进展和潜在处罚结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMZ","HEAL","GLAM","BK4196","HIYY","HMYY","HIMY","THNR","HIMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655892781","title":"獨家報導-美國聯邦貿易委員會（FTC）起訴Hims & Hers公司，指控其向Meta和Snap泄露用户健康信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2655892781","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655892781?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 00:30","pubTimestamp":1785342638,"startTime":"0","endTime":"0","summary":"独家报导-美国联邦贸易委员会起诉Hims & Hers公司，指控其向Meta和Snap泄露用户健康信息Jody Godoy路透7月29日-美国联邦贸易委员会的一位发言人表示，该委员会正在起诉Hims & Hers，指控这家远程医疗平台尽管承诺保护隐私，却仍将用户的健康数据分享给在线广告商，并存在欺骗性的计费和取消服务行为。FTC还计划指控称，Hims & Hers还故意设置障碍，使用户难以取消订阅。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL4T43V1U1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HMYY","GLAM","HEAL","BK4196","HIMS","THNR","HIMY","HIYY","HIMZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655863822","title":"傑富瑞上調雅詩蘭黛目標價至88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655863822","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655863822?lang=zh_tw&edition=fundamental","pubTime":"2026-07-29 17:16","pubTimestamp":1785316594,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4533","LU2552382215.SGD","LU2404859667.USD","BK4588","BK4183","BK4558","GLAM","UDN","BK4548","LU0690374615.EUR","LU2404859741.USD","LU0690374961.EUR","LU2264538146.SGD","LU2552382058.USD","BK4504","EL","BK4585","LU1988902786.USD","LU2552382132.HKD","UUP","LU1064131342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655889943","title":"艾伯維(ABBV)股票7月28日盤中上漲3.35%：關鍵驅動因素揭曉","url":"https://stock-news.laohu8.com/highlight/detail?id=2655889943","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655889943?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 23:16","pubTimestamp":1785251791,"startTime":"0","endTime":"0","summary":"• Skyrizi和Rinvoq的增长抵消了修美乐（Humira）生物类似药竞争带来的收入损失。\n• 在公布强劲的季度业绩后，艾伯维上调了全年调整后盈利指引。\n• 神经科学和肿瘤学领域积极的后期临床试验数据推动了中期增长。","market":"sg","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262059169-market-movers-abbv-20260728","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3PB1722.GBP","XLV","LU1989771016.USD","GLAM","LU1061106388.HKD","LU0203347892.USD","LU1162221912.USD","LU1267930490.SGD","LU2087621335.USD","LU2129689605.HKD","LU0943347566.SGD","LU2433249047.HKD","LU1267930573.SGD","LU0472753341.HKD","FHLC","LU1057294990.SGD","TRUH","RXL","LU0882574055.USD","SG9999003800.SGD","LU2133065610.SGD","LU0124676726.USD","LU0198837287.USD","IE0002141913.USD","LU2089984988.USD","PJP","ABBV","IE00BJJMRZ35.SGD","FTXH","LU0861579265.USD","MEDX","AGNG","LU0170899867.USD","LU0868494617.USD","IE00BGHQF631.EUR","BK4585","LU2347655156.SGD","IXJ","PPH","IE00B42XCP33.USD","LU1670628061.USD","IE000BZT7R73.USD","LU2357627491.SGD","VHT","IE00BJT1NW94.SGD","IE0009355771.USD","IE00BDGV0183.EUR","LU0942090050.USD","JDOC","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654007935","title":"解讀世界500強排行榜醫藥板塊：強生繼續「霸榜」，禮來排名上升112位，3家中國企業入選","url":"https://stock-news.laohu8.com/highlight/detail?id=2654007935","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654007935?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 20:51","pubTimestamp":1785243108,"startTime":"0","endTime":"0","summary":"7月28日，2026年《财富》世界500强榜单正式发布。《每日经济新闻》记者注意到，医疗健康板块作为全球五大支柱行业之一，共有31家企业上榜。其中，礼来公司排名从2025年的336位上升至今年的224位，成为今年上涨最快的10家公司之一。中国公司中，中国医药集团、上海医药、广药集团3家公司再次入围。《每日经济新闻》记者注意到，位居医疗健康相关企业榜首的是联合健康集团。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607283823749452.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607283823749452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0528227936.USD","LU1430594728.SGD","BK4568","LU2756315318.SGD","IE00BJLML261.HKD","LU1804176565.USD","THNR","AMGN","IE00B1XK9C88.USD","IE00BJJMRZ35.SGD","LU2361044865.SGD","LU0158827781.USD","LU0170899867.USD","LU0225771236.USD","LU0661504455.SGD","SG9999014914.USD","LU0882574139.USD","LU0342679015.USD","LU0124676726.USD","SG9999017495.SGD","IHE","LU2552382058.USD","LU2265009873.SGD","SG9999015945.SGD","LU2362541513.USD","LU0648001328.SGD","LU0289739343.SGD","PFE","IE000SO60NU8.SGD","LU0466842654.USD","LU0079474960.USD","IE00BVYPNW00.USD","LU2125154935.USD","IE0034235303.USD","LU1261432733.SGD","IE00BKPKM429.USD","LU1119994496.HKD","LU2756315664.SGD","SG9999018865.SGD","ILDR","LU1244550494.USD","LU0820561909.HKD","LU0889566641.SGD","IE0009355771.USD","LU0792757196.USD","LU2264538146.SGD","IE0005OL40V9.USD","IE00BKVL7J92.USD","LU0316494557.USD","IE00BVYPNV92.GBP","IE00B19Z8W00.USD","LU0256863811.USD","LU0211328371.USD","LU0070302665.USD","LU1718418525.SGD","BK4578","LU2347655073.USD","LU0234572021.USD","LU0868494617.USD","LU0238689110.USD","LU0882574055.USD","LU1267930730.SGD","LU0320765992.SGD","LU2242652126.USD","PJP","LU2125909247.SGD","LU1989772840.SGD","LU0345769631.USD","LU1084165304.USD","LU2168564222.USD","IE00BGHQF631.EUR","LU1571399168.USD","LU2129689605.HKD","IE00B19Z9P08.USD","LU0187121727.USD","IE0004445239.USD","IE00BJJMRX11.SGD","CANC","LU0310799852.SGD","BIB","LU1228905037.USD","SG9999014567.USD","LU1506573853.SGD","IE00BKDWB100.SGD","LU0964807845.USD","LU0786609619.USD","BK4559","LU1221951129.SGD","IE00BFTCPJ56.SGD","IE00B7SZLL34.SGD","LU1267930573.SGD","LU0114720955.EUR","GB00BDT5M118.USD","LU1093756168.USD","LU0256863902.USD","LU1854104046.USD","LU1066051811.HKD","LU1712237335.SGD","LU2213496289.HKD","LU0057025933.USD","LU0210536198.USD","LU1037948541.HKD","SG9999015986.USD","SG9999014575.USD","LU0094547139.USD","LU2028103732.USD","LU0011850046.USD","IE00B4R5TH58.HKD","IE00BK4W5L77.USD","LU2237443978.SGD","LU1699723380.USD","LU1923622614.USD","LU0321505868.SGD","RHHBY","LU0417517546.SGD","LU0210528500.USD","LU0942090050.USD","LU1839511570.USD","LU2462591277.SGD","SG9999014880.SGD","SGXZ31699556.SGD","LU1988902786.USD","LU2491050154.USD","LU2063271972.USD","IE000WAW04H5.SGD","LU0174119429.USD","IE00BLSP4239.USD","LU0203347892.USD","LU1732799900.SGD","BK4533","LU1035775433.USD","LU2471134796.USD","LU0738911758.USD","LU0868494708.USD","LU2596442595.SGD","LU1323610961.USD","LU2129689431.USD","LU2087621335.USD","LU1121112475.USD","LU2089283258.USD","LU2403377893.USD","LU1929549753.HKD","LU0266013472.USD","LU0143551892.USD","LU0965509010.AUD","LU1496350502.SGD","LU0225283273.USD","LU2361044949.HKD","LU0310800379.SGD","BK4550","LU2433249047.HKD","BMED","IHF","NVS","TRUH","IE00BFXG1179.USD","LU2954938101.SGD","LU0098860793.USD","LU2089284900.SGD","LU2089984988.USD","IE0004445015.USD","LU2357305700.SGD","LU1883839398.USD","LU2430703178.SGD","UNHW","LU1941712348.USD","LU1791710582.SGD","LU2360032135.SGD","LU0496365809.HKD","BK4588","LU2347655156.SGD","LU0823416689.USD","GDOC","BK4534","LU1069344957.HKD","LU0289961442.SGD","LU0029864427.USD","SG9999014898.SGD","LU0203202063.USD","BK4581","LU0149725797.USD","LU0354030511.USD","LU0640476718.USD","LU0965508806.USD","LU2133065610.SGD","LU1551013425.SGD","IE0001KFT4U8.USD","LU0471298777.SGD","LU2168563687.JPY","LU2430703095.HKD","BK4532","LU2602419157.SGD","LU2552382132.HKD","LU0077335932.USD","LU0225284248.USD","LU1894683348.USD","LU2129689514.USD","LU0980610538.SGD","IE00B4JS1V06.HKD","MRK","LU2362541273.HKD","IE000MB6IJN5.SGD","LU0061475181.USD","LU1791710400.SGD","LU0949170772.SGD","IE0002270589.USD","IE00BN29S564.USD","IE00B775H168.HKD","LU1732800096.USD","LU2023250330.USD","LU1291159041.SGD","LU1941712264.USD","LU2237438978.USD","SG9999015952.SGD","LU0130517989.USD","LU2750360997.AUD","UNHG","LU1228905540.USD","SG9999003800.SGD","JNJ","LU1232071149.USD","ABBV","LU2237443549.SGD","IE00BN8TJ469.HKD","LU1064131342.USD","LU2125909593.SGD","LU1032466523.USD","LU0234570918.USD","LU1496350171.SGD","LU2462157665.USD","IE00BDGV0183.EUR","TMED","LU0823434740.USD","LU1720051017.SGD","LU2456880835.USD","LLY","LU2592432038.USD","LU1629891620.HKD","LU0557290698.USD","JDOC","LU0128525929.USD","UNH","XLV","LU0251132253.USD","LU2236285917.USD","LU0708995401.HKD","LU2023250504.SGD","LU2106854487.HKD","LU2111349929.HKD","LU0323591593.USD","LU0320765059.SGD","LU0861579265.USD","LU2168564149.EUR","LU0133085943.USD","LU1066051225.USD","LU0109394709.USD","CURE","BBH","LU2357627491.SGD","LU1244550221.USD","SG9999001176.USD","LLYX","LU1868836914.USD","IE00B19Z3581.USD","LU2471134523.USD","LU0545039389.USD","LU2279689827.SGD","BK4007","LU0208291251.USD","IE00BWXC8680.SGD","LU0683600562.USD","LU1366192091.USD","LU2023250843.SGD","LU0353189680.USD","LU0070217475.USD","LU0265550946.USD","IE0000B7K699.USD","LU0211331839.USD","LU0385154629.USD","LU0689472784.USD","LU0107464264.USD","LU1974910355.USD","SG9999002224.SGD","PAWZ","LU1548497426.USD","LU0426417589.USD","LU0912757837.SGD","SG9999015341.SGD","IE000M9KFDE8.USD","IE00BLSP4452.SGD","LU2271345857.HKD","LU2471134879.HKD","LU0823434583.USD","LU0203345920.USD","WDNA","LU2023251221.USD","LU2087625088.SGD","LU2237443895.HKD","SGXZ99366536.SGD","LU0726765562.USD","LU1061106388.HKD","LU0289739699.SGD","LU1043141396.HKD","LU1244550577.SGD","FHLC","LU0545562505.USD","LU1221951046.USD","LU1935042991.SGD","LU1989771016.USD","SG9999015978.USD","LU2746668974.SGD","LU1127390331.HKD","IE00B19Z3B42.SGD","LU0052756011.USD","LU0211327993.USD","LU1894683264.USD","LU1623119135.USD","LU2750360641.GBP","LU2505996509.AUD","LU1057294990.SGD","LU2211815571.USD","LU2491050071.SGD","BK4566","BK4585","LU1043141123.HKD","IBBQ","IXJ","IE00B19Z8X17.USD","IE00B894F039.SGD","LU0345770308.USD","LU1551013342.USD","LU0471298694.HKD","LU1983299246.USD","LU1201861249.SGD","LU0965509101.SGD","LU0122379950.USD","LU0672654240.SGD","NVOX","LU0130102774.USD","LU1116320901.HKD","LU0787776722.HKD","BK4592","VHT","LU1069347547.HKD","LU0198837287.USD","ELIS","SGXZ81514606.USD","PBE","IBB","LU2237443382.USD","LU0345770993.USD","LU2112291526.USD","SG9999013999.USD","LU1074936037.SGD","LU1032955483.USD","HRTS","LU0211326839.USD","LU2237443622.USD","LU0943347566.SGD","LU2487616109.SGD","UNHU","IE00B3PB1722.GBP","BK4139","LU0708994859.HKD","LU2746668461.USD","SGXZ51526630.SGD","LU0965509283.SGD","LU1914381329.SGD","LU2552382215.SGD","IE00B3T34201.USD","LU0058720904.USD","IE000F7OJYX1.SGD","LU0477156953.USD","LU1868836757.USD","LLII","OZEM","LU0211326755.USD","LU1670627923.USD","LU0128525689.USD","LU0553294199.USD","LU2242649171.HKD","LU2417539215.USD","LU1093756325.SGD","LU0109391861.USD","LU1814569148.SGD","SG9999018857.SGD","RXL","LU2999663052.SGD","LU0472753341.HKD","LU0320765646.SGD","LU0395794307.EUR","SGXZ57979304.SGD","LU2242646821.SGD","LU1023059063.AUD","IE00B1BXHZ80.USD","LU1868837300.USD","LU0158827948.USD","LU0432979614.USD","LU0069063385.USD","IYH","LU0354030438.USD","LU1162221912.USD","IE00BZ9MQY76.HKD","IE00BJJMRY28.SGD","MEDX","IE00B2B36J28.USD","IE00BFSS8Q28.SGD","LU0689626769.HKD","LU0795875086.SGD","LU0265550359.USD","LU1670628061.USD","BK4599","IE00B19Z9505.USD","LU0106261372.USD","LU0006306889.USD","SG9999002232.USD","LU2505996681.GBP","LU1854103824.USD","LU0456855351.SGD","LU1267930813.SGD","LU1066051498.USD","LU1196500208.SGD","NVOH","LU2461242641.AUD","LU2362540622.SGD","LU0994945656.USD","LU1145028129.USD","PPH","LU0096364046.USD","LU1059921491.USD","SG9999014559.SGD","LU2168564065.EUR","SG9999001176.SGD","LU0310800965.SGD","IE00BBT3K403.USD","LU0321505439.SGD","LU1035773651.USD","NVO","LU1868837136.USD","LU1674673691.USD","LU0306807586.USD","IE00BJT1NW94.SGD","LU1003077747.HKD","LU2360106947.USD","LU1934455863.HKD","04332","IE0002141913.USD","MEDI","IE00BZ1G4Q59.USD","LU2361045086.USD","LU1989772923.USD","SG9999015358.SGD","IE00BFSS7M15.SGD","LU0820561818.USD","LU0795875169.SGD","LU0985481810.HKD","LU2244417387.USD","LU0345769128.USD","LU0820562030.AUD","LU2237443465.HKD","LU1153585028.USD","LU0072461881.USD","LU0203201768.USD","LU1934455277.USD","GLAM","BK4516","LU1934455194.USD","LU0162691827.USD","LU0889565916.HKD","LU1868836591.USD","LU1674673428.USD","LU2462591350.SGD","LU2471134952.CNY","LU2430703251.USD","LU0511384066.AUD","LLYZ","LU1116320737.USD","LU0353189763.USD","LU2125154778.USD","SG9999001440.SGD","LU0154236417.USD","LU1267930490.SGD","LU0306806265.USD","LU1066053197.SGD","LU2491049909.HKD","LU1720051108.HKD","LU1585245621.USD","LU1778281490.HKD","LU1917777945.USD","TBXU","LU0320765489.SGD","LU0859254822.USD","LU0097036916.USD","IE00B19Z9Z06.USD","LU2324357040.USD","ELIL","LU0053666078.USD","AGNG","IE00BK4W5M84.HKD","SG9999011175.SGD","SG9999014906.USD","IE00BSNM7G36.USD","IE000BZT7R73.USD","MHIP","LU0048584097.USD","LU2168564495.EUR","LU1280957306.USD","SG9999014542.SGD","LU0426412945.USD","BK4154","LU0985320562.USD","FTXH","BK4504","IE00B7KXQ091.USD","IE00B42XCP33.USD","LU1267930227.SGD","LU2896262040.SGD","LU2468319806.SGD","LU0976567544.SGD","LU2108987350.USD","03165","LU1037948897.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654407006","title":"Meta和貝萊德將在德克薩斯州EL Paso開發數據中心園區 由後者持股80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654407006","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654407006?lang=zh_tw&edition=fundamental","pubTime":"2026-07-28 17:42","pubTimestamp":1785231720,"startTime":"0","endTime":"0","summary":"根据声明，Meta和贝莱德成立了一家合资企业，将在德克萨斯州El Paso开发和持有数据中心园区。\n　　贝莱德的基金将持有80%的权益；Meta持有剩余的20%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：江学思","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-28/doc-inikizzz2507496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["PBOT","LU2592432038.USD","TSLA","IE00BVYPNV92.GBP","CLDL","FMET","BLOK","BK4533","WISE","BULZ","NVDA","BK4535","FDFF","IE00BGHQF748.EUR","LU0731783394.SGD","LU2404859667.USD","HPEL","MAGY","EL","LU2505996681.GBP","AAPL","IE00BDGV0183.EUR","FCLD","BLK","YMAG","GLAM","AIFD","LU1280957306.USD","DTCR","GOOG","BK4548","AIO","IE00B64PRP62.GBP","WDAI","CLOU","IDGT","IE00BGHQF631.EUR","WPAI","META","AIBU","LU2552382215.SGD","MSFT","SOCL","LU0320765489.SGD","LU2430703251.USD","SKYY","LU0130102774.USD","BK4183","BK4567"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654482830","title":"Sarepta任命前艾伯維高管塞韋裏諾為首席執行官後股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2654482830","media":"路透中文","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654482830?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 21:05","pubTimestamp":1785157512,"startTime":"0","endTime":"0","summary":"BUZZ-Sarepta任命前艾伯维高管塞韦里诺为首席执行官后股价上涨7月27日-** 基因治疗公司Sarepta Therapeutics的股价在盘前交易中上涨7.1%，至16.8美元** 该公司任命  的迈克尔·塞韦里诺为首席执行官，自7月28日起生效** 塞韦里诺将接替道格·英格拉姆的职位，后者即将退休，并将担任顾问职务至年底，以确保平稳过渡**在加入该公司之前，塞韦里诺曾担任Tessera Therapeutics的首席执行官，此前还曾在艾伯维担任副董事长兼总裁ABBV.O** 截至上一交易日收盘，该股今年以来累计下跌27.1%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL4T43T11Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0689626769.HKD","LU0965508806.USD","LU0553294199.USD","SG9999015986.USD","IE000BZT7R73.USD","LU1934455277.USD","LU1670627923.USD","SG9999001440.SGD","BK4533","IYH","LU0868494617.USD","SRPU","GLAM","IXJ","IE00B2B36J28.USD","SRPT","FTXH","LU2237443978.SGD","BK4534","JDOC","TRUH","LU0310799852.SGD","RXL","PPH","LU0234572021.USD","BK4559","IE00B4R5TH58.HKD","FHLC","IE0009355771.USD","LU2433249047.HKD","LU0203345920.USD","LU0965509010.AUD","LU1989772840.SGD","LU1244550221.USD","LU1732799900.SGD","ABBV","LU0170899867.USD","PJP","XLV","LU0289739343.SGD","AGNG","IE000F7OJYX1.SGD","IE00BVYPNV92.GBP","MEDX","BK4550","LU0949170772.SGD","VHT","LU1037948897.HKD","LU0820561909.HKD","LU0689472784.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106583056","title":"Kenvue 宣佈：FDA 授予泰諾新非處方配方三年市場獨佔權","url":"https://stock-news.laohu8.com/highlight/detail?id=1106583056","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106583056?lang=zh_tw&edition=fundamental","pubTime":"2026-07-25 02:17","pubTimestamp":1784917050,"startTime":"0","endTime":"0","summary":"7月24日——Kenvue 公司披露，美国食品药品监督管理局已正式批准泰诺与萘普生的复方制剂。这是市面上首款，也是唯一一款含有对乙酰氨基酚和萘普生钠的非处方固定剂量组合产品。不仅如此，FDA还授予了该新配方长达三年的市场独占权。这一举措，无疑为Kenvue在非处方止痛药领域的布局提供了坚实的护城河。据Kenvue方面透露，这款名为“泰诺与萘普生”的新品很快将在美国各大主要零售商上架销售。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","LU1267930573.SGD","LU0708994859.HKD","GLAM","LU0029864427.USD","LU1267930813.SGD","BK4585","KVUE","LU0792757196.USD","RSPS","LU0128525929.USD","IE00B3T34201.USD","BK4588","LU0310800379.SGD","BK4183","LU0889566641.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128949873","title":"FDA批准泰諾®與萘普生複方製劑：首款非處方對乙酰氨基酚（650毫克）與萘普生鈉（220毫克）固定劑量組合","url":"https://stock-news.laohu8.com/highlight/detail?id=1128949873","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128949873?lang=zh_tw&edition=fundamental","pubTime":"2026-07-25 02:01","pubTimestamp":1784916077,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式批准泰诺®与萘普生复方制剂上市。这款产品是首款且唯一一款非处方固定剂量组合药物，其成分为对乙酰氨基酚（650毫克）与萘普生钠（220毫克）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0792757196.USD","IE00B3T34201.USD","RSPS","BK4183","GLAM","LU0889566641.SGD","LU1267930573.SGD","LU0708994859.HKD","LU0128525929.USD","LU1267930813.SGD","BK4588","BK4585","KVUE","IE00BFXG1179.USD","LU0029864427.USD","LU0310800379.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653035035","title":"美國FDA批准非處方泰諾複方止痛片","url":"https://stock-news.laohu8.com/highlight/detail?id=2653035035","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653035035?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 23:56","pubTimestamp":1784908596,"startTime":"0","endTime":"0","summary":"美国FDA批准非处方泰诺复方止痛片路透7月24日-美国食品和药物管理局周五批准了一种非处方固定剂量片剂，该药将Kenvue公司的KVUE.N泰诺与非甾体抗炎药萘普生结合，可提供长达12小时的止痛效果。FDA表示，此次批准符合特朗普的“伟大医疗计划”，该联邦计划旨在让更多经过验证的安全药品可供非处方购买。此前，美国卫生官员对孕期服用泰诺与自闭症之间据称存在的关联表示担忧，泰诺因此受到密切关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nL4S43Q1CZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1585245621.USD","LU1430594728.SGD","LU0708994859.HKD","KMB","IE00B3T34201.USD","BK4588","KVUE","BK4183","LU0310800379.SGD","LU0889566641.SGD","GLAM","LU0128525929.USD","LU1571399168.USD","LU0029864427.USD","LU0792757196.USD","LU2463526074.USD","RSPS","BK4504","BK4018","BK4585","IE00BFXG1179.USD","BK4567","LU1267930813.SGD","SG9999001440.SGD","LU1267930573.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164500582","title":"美國FDA批准首款對乙酰氨基酚/萘普生非處方組合產品——泰諾聯用萘普生，提供12小時鎮痛效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1164500582","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164500582?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 22:48","pubTimestamp":1784904499,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）近日正式批准了泰诺（Tylenol）与萘普生（Naproxen）的联合用药方案。这是首款非处方（OTC）复方制剂，将对乙酰氨基酚（Acetaminophen）与萘普生（Naproxen）合二为一，专为缓解疼痛而设计，其药效可长达12小时。这一创新组合，有望为饱受疼痛困扰的患者提供更持久、更便捷的镇痛选择，无需频繁服药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930573.SGD","IE00B3T34201.USD","BK4588","LU0310800379.SGD","KVUE","RSPS","LU0889566641.SGD","IE00BFXG1179.USD","LU0029864427.USD","BK4585","LU1267930813.SGD","LU0128525929.USD","LU0708994859.HKD","LU0792757196.USD","GLAM","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108936974","title":"艾利科技推出全新創新成果，藉助整合型Align™數字平台提升Invisalign®治療方案規劃與患者參與度","url":"https://stock-news.laohu8.com/highlight/detail?id=1108936974","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108936974?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 04:43","pubTimestamp":1784839410,"startTime":"0","endTime":"0","summary":"艾利科技（Align Technology）近日宣布一系列全新创新举措。这些成果旨在进一步推动Invisalign®治疗方案规划的进步。同时，通过其整合型Align™数字平台，患者参与度也将得到显著增强。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","ALGN","LU1917777945.USD","BK4504","LU2023250843.SGD","GLAM","LU2106854487.HKD","BK4198","LU1974910355.USD","BK4588","BK4585","LU2023250504.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135293473","title":"Genmab與艾伯維就Epcoritamab（Duobody®-CD3xCD20）治療復發/難治性瀰漫大B細胞淋巴瘤的3期EPCORE® DLBCL-1試驗作出澄清","url":"https://stock-news.laohu8.com/highlight/detail?id=1135293473","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135293473?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 04:01","pubTimestamp":1784836901,"startTime":"0","endTime":"0","summary":"Genmab与艾伯维公司（AbbVie）日前就备受关注的3期EPCORE® DLBCL-1临床试验发布了最新澄清说明。该试验旨在全面评估Epcoritamab（Duobody®-CD3xCD20）这一创新疗法在复发或难治性弥漫大B细胞淋巴瘤（DLBCL）患者中的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0553294199.USD","LU1037948541.HKD","IE00B19Z3B42.SGD","LU1732800096.USD","LU1551013425.SGD","BK4585","LU0114720955.EUR","LU1551013342.USD","LU0098860793.USD","LU2468319806.SGD","LU1003077747.HKD","LU2347655156.SGD","IXJ","LU0511384066.AUD","LU2237443895.HKD","LU0868494708.USD","LU0882574055.USD","LU2357627491.SGD","LU0256863902.USD","BK4559","SG9999003800.SGD","LU0661504455.SGD","IE0009355771.USD","LU0289961442.SGD","LU0965509010.AUD","LU1989772840.SGD","IE00B42XCP33.USD","LU1162221912.USD","LU1718418525.SGD","IE00BJJMRZ35.SGD","LU0170899867.USD","PJP","IE000F7OJYX1.SGD","IE000SO60NU8.SGD","IE000WAW04H5.SGD","LU0738911758.USD","LU1093756168.USD","IE00B3PB1722.GBP","LU1585245621.USD","LU0158827948.USD","LU0689626769.HKD","IE00BVYPNW00.USD","LU1244550494.USD","LU1496350502.SGD","LU2089284900.SGD","LU1934455277.USD","LU0211328371.USD","LU1983299246.USD","SG9999001440.SGD","LU2125909593.SGD","IE0004445239.USD","LU0868494617.USD","IE0002141913.USD","LU1989772923.USD","IE00BLSP4452.SGD","FTXH","LU1291159041.SGD","BK4534","LU0289739699.SGD","LU0310799852.SGD","RXL","BK4581","LU0234572021.USD","LU0472753341.HKD","BK4566","LU2133065610.SGD","LU0203345920.USD","LU0234570918.USD","LU0122379950.USD","LU0859254822.USD","IE00BSNM7G36.USD","LU2089984988.USD","LU0965509101.SGD","LU0289739343.SGD","LU1023059063.AUD","AGNG","LU1057294990.SGD","IE0000B7K699.USD","BK4550","LU0949170772.SGD","LU1074936037.SGD","LU1037948897.HKD","VHT","LU2112291526.USD","LU2089283258.USD","LU0069063385.USD","LU1267930490.SGD","SG9999015986.USD","IE00BGHQF631.EUR","LU2237443465.HKD","LU0795875086.SGD","LU1093756325.SGD","LU1934455863.HKD","LU1244550577.SGD","IE00BFTCPJ56.SGD","GLAM","IE00B2B36J28.USD","LU1929549753.HKD","LU2125909247.SGD","LU2237443978.SGD","LU0058720904.USD","SG9999015978.USD","LU0417517546.SGD","PPH","LU1934455194.USD","LU1430594728.SGD","IE00B4R5TH58.HKD","LU0545039389.USD","LU1670628061.USD","LU0942090050.USD","LU1267930573.SGD","LU2129689514.USD","SG9999015945.SGD","LU2237443549.SGD","LU0820561818.USD","LU2129689431.USD","LU0708994859.HKD","IE00BVYPNV92.GBP","MEDX","IE00BBT3K403.USD","LU0203347892.USD","XLV","SG9999011175.SGD","LU0820561909.HKD","LU0965509283.SGD","LU0965508806.USD","LU2237443382.USD","IE00BDGV0183.EUR","IE0002270589.USD","IE000BZT7R73.USD","LU1670627923.USD","BK4533","IYH","LU2023251221.USD","LU0943347566.SGD","IE000MB6IJN5.SGD","LU0320765646.SGD","SG9999015952.SGD","LU0912757837.SGD","BK4139","JDOC","TRUH","LU0823416689.USD","IE00B19Z3581.USD","LU0211327993.USD","BK4588","LU0057025933.USD","FHLC","LU0198837287.USD","LU1839511570.USD","LU0256863811.USD","LU2433249047.HKD","LU1989771016.USD","LU1244550221.USD","IE00BN8TJ469.HKD","LU1061106388.HKD","LU2087621335.USD","LU1496350171.SGD","LU0985320562.USD","LU1732799900.SGD","LU0124676726.USD","ABBV","IE00BJT1NW94.SGD","LU0456855351.SGD","LU0029864427.USD","LU0432979614.USD","LU2237443622.USD","LU0128525929.USD","LU2129689605.HKD","LU1923622614.USD","LU0310800379.SGD","LU0795875169.SGD","IE00BLSP4239.USD","LU0861579265.USD","LU0689472784.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116716506","title":"Genmab澄清：總生存期（OS）作為美國3期Epcore® DLBCL-1試驗的唯一主要終點，但未能達到","url":"https://stock-news.laohu8.com/highlight/detail?id=1116716506","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116716506?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 04:01","pubTimestamp":1784836871,"startTime":"0","endTime":"0","summary":"Genmab公司近日发布声明，对关于其3期Epcore® DLBCL-1临床试验的结果进行了进一步澄清。该公司明确指出，总生存期（OS）是此项试验在美国设定的唯一主要终点。然而，令人遗憾的是，这一关键终点最终并未能成功达到。\n此声明旨在厘清外界对试验数据的理解，避免不必要的误读。总生存期作为衡量患者从治疗开始到死亡时间的最直接指标，其未达到预期结果，对Genmab而言无疑是一个重大挫折。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0689472784.USD","LU2237443549.SGD","LU2125909593.SGD","LU1551013342.USD","LU0943347566.SGD","BK4585","LU0289739343.SGD","LU0310799852.SGD","IE00B19Z3581.USD","IE00BDGV0183.EUR","IE00BJT1NW94.SGD","IE0000B7K699.USD","IXJ","IE0002141913.USD","LU0198837287.USD","AGNG","LU0738911758.USD","LU2237443465.HKD","LU2468319806.SGD","LU0417517546.SGD","LU1989772840.SGD","LU0553294199.USD","XLV","LU0965509101.SGD","LU0859254822.USD","LU0124676726.USD","LU0203347892.USD","LU0861579265.USD","IE0002270589.USD","LU0545039389.USD","LU1244550577.SGD","MEDX","LU1732800096.USD","LU1023059063.AUD","LU2125909247.SGD","LU2089984988.USD","LU1929549753.HKD","LU0029864427.USD","LU0098860793.USD","LU0689626769.HKD","LU1989772923.USD","BK4566","BK4559","LU1989771016.USD","IE00BVYPNV92.GBP","LU1551013425.SGD","IE000F7OJYX1.SGD","LU0069063385.USD","SG9999001440.SGD","LU2129689605.HKD","IE000MB6IJN5.SGD","LU0820561909.HKD","IE00BVYPNW00.USD","LU2129689431.USD","LU1923622614.USD","LU2087621335.USD","LU1061106388.HKD","LU1074936037.SGD","LU0122379950.USD","IE0009355771.USD","FTXH","IE00B42XCP33.USD","IE00BSNM7G36.USD","JDOC","LU0882574055.USD","LU0985320562.USD","LU0820561818.USD","LU0114720955.EUR","IE00BLSP4452.SGD","LU0170899867.USD","LU1267930490.SGD","LU0203345920.USD","LU0256863902.USD","LU1496350502.SGD","LU0289739699.SGD","LU1934455194.USD","BK4588","LU1496350171.SGD","LU0058720904.USD","LU0211327993.USD","LU0256863811.USD","LU1267930573.SGD","LU2129689514.USD","LU1718418525.SGD","LU1585245621.USD","LU2089284900.SGD","LU1244550494.USD","LU0456855351.SGD","SG9999015978.USD","LU1162221912.USD","LU0823416689.USD","ABBV","IE000WAW04H5.SGD","LU2089283258.USD","LU0289961442.SGD","LU0942090050.USD","LU1670628061.USD","LU2433249047.HKD","IE00BLSP4239.USD","LU0708994859.HKD","IE00B19Z3B42.SGD","LU2133065610.SGD","LU1037948541.HKD","LU0128525929.USD","LU2347655156.SGD","LU0661504455.SGD","LU2237443622.USD","IE00B2B36J28.USD","BK4139","LU2023251221.USD","IE000SO60NU8.SGD","VHT","LU0511384066.AUD","LU0432979614.USD","IYH","BK4581","LU2237443382.USD","LU1670627923.USD","LU0868494708.USD","PJP","LU0472753341.HKD","LU0795875086.SGD","IE000BZT7R73.USD","SG9999003800.SGD","LU1291159041.SGD","LU0234572021.USD","LU1934455277.USD","LU0965509010.AUD","IE00B3PB1722.GBP","LU0965508806.USD","PPH","IE00BBT3K403.USD","LU1093756168.USD","LU0949170772.SGD","LU1093756325.SGD","LU1057294990.SGD","LU2357627491.SGD","LU2237443978.SGD","SG9999015952.SGD","TRUH","LU0868494617.USD","SG9999011175.SGD","LU1732799900.SGD","LU0965509283.SGD","LU0234570918.USD","IE00BJJMRZ35.SGD","BK4550","LU2237443895.HKD","IE00BFTCPJ56.SGD","LU0211328371.USD","LU2112291526.USD","LU1003077747.HKD","FHLC","IE00BGHQF631.EUR","IE00BN8TJ469.HKD","LU0310800379.SGD","LU1430594728.SGD","LU1839511570.USD","SG9999015986.USD","LU0158827948.USD","BK4534","IE00B4R5TH58.HKD","LU0057025933.USD","LU0912757837.SGD","LU1244550221.USD","BK4533","GLAM","SG9999015945.SGD","LU1983299246.USD","LU0795875169.SGD","IE0004445239.USD","LU0320765646.SGD","RXL","LU1037948897.HKD","LU1934455863.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109432677","title":"FDA顧問委員會投票支持將Bpc-157肽納入允許藥房配製清單，Hims & Hers Health股價飆升10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109432677","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109432677?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 00:51","pubTimestamp":1784825499,"startTime":"0","endTime":"0","summary":"Hims & Hers Health Inc.股价上涨10%。这一涨势的催化剂是什么？FDA顾问委员会刚刚投票决定，将Bpc-157肽列入允许药房配制的清单中。该决定一经公布，市场随即作出强烈反应。投资者普遍认为，此举将为相关公司开辟新的业务增长路径。Bpc-157作为一种备受关注的肽类物质，如今获得监管层面的积极信号，无疑让市场情绪瞬间高涨。从消息公布到股价反应，整个过程可谓迅速而剧烈，显示出投资者对该领域前景的高度期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HEAL","HIMS","BK4196","HIMZ","THNR","HMYY","HIYY","GLAM","HIMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653837722","title":"FDA顧問小組投票決定將廣受歡迎的肽BPC-157列入複方製劑清單","url":"https://stock-news.laohu8.com/highlight/detail?id=2653837722","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653837722?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 00:43","pubTimestamp":1784824996,"startTime":"0","endTime":"0","summary":"FDA顾问小组投票决定将广受欢迎的肽BPC-157列入复方制剂清单路透7月23日-美国食品和药物管理局（FDA）的一个顾问小组周四投票决定，将一种名为BPC-157的广泛使用的肽列入允许药房进行更广泛配制的清单。八名委员会成员投了赞成票，六名成员投了反对票，一名成员弃权。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nL4T43P263:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMS","GLAM","HMYY","HIYY","BK4196","HIMY","HEAL","HIMZ","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653724664","title":"美國FDA顧問小組評估肽類限制，業界促放寬","url":"https://stock-news.laohu8.com/highlight/detail?id=2653724664","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653724664?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 00:09","pubTimestamp":1784822960,"startTime":"0","endTime":"0","summary":"拜登政府于2023年发现近20种肽类药物存在安全隐患，并禁止其合法配制。FDA 敦促开展临床试验目前已有许多肽类药物获得了卫生监管机构的批准。而此次会议中正在评估的药物尚未经过此类临床试验，且可在网上轻易购买，无需任何医生监督。FDA的评审人员上个月在文件中曾向专家小组建议，该机构不应支持允许持有州执照的配制药房进行此类操作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nL4S43P23A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","HIYY","HEAL","HIMS","HMYY","HIMY","GLAM","HIMZ","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159771566","title":"遠程醫療公司Hims & Hers力促FDA放寬部分肽類准入，股價上漲2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159771566","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159771566?lang=zh_tw&edition=fundamental","pubTime":"2026-07-23 22:32","pubTimestamp":1784817171,"startTime":"0","endTime":"0","summary":"在小组会议中，远程医疗企业Hims & Hers Health Inc.（股票代码：HIMS）积极呼吁美国食品药品监督管理局（FDA）扩大对特定肽类药物的可及性。这一消息传出后，该公司股价应声上扬，涨幅达到2%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","HEAL","BK4196","HIMS","GLAM","HIMY","HMYY","HIMZ","HIYY"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":7,"totalSize":145,"code":"91000000","status":"200"}]}}